Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an investment foundation of Novo Nordisk, acquired three manufacturing sites in ...

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

The TV spot marks the artificial-intelligence company's biggest foray into consumer advertising to date. Tesla sales careened lower in Germany in January, as sales of the electric vehicle company ...

Overall U.S. exports to the world grew to $3.19 trillion in 2024, up 3.9 percent from the previous year, as the United States ...

The shaving giant is looking for around 250,000 square feet of office space as it prepares to move out of, and then perhaps ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...